Search
Close this search box.

Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

Primary Sponsor

ANZUP

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre

Accrual Target

800

Final Accrual

802

Closing Date of Accrual

30 June 2018

Trial Contact

enzarad.study@sydney.edu.au

Related Post

Trek4TROG team 2024 in Blue Mountains
13 November, 2024

Trek4TROG team rise to Blue Mountains challenge

November 2024: Congratulations to the Trek4TROG team for successfully

24 October, 2024

Promising new results from RAIDER trial published

24 October 2024: Newly published findings from the TROG